JP2022513116A5 - - Google Patents

Info

Publication number
JP2022513116A5
JP2022513116A5 JP2021529003A JP2021529003A JP2022513116A5 JP 2022513116 A5 JP2022513116 A5 JP 2022513116A5 JP 2021529003 A JP2021529003 A JP 2021529003A JP 2021529003 A JP2021529003 A JP 2021529003A JP 2022513116 A5 JP2022513116 A5 JP 2022513116A5
Authority
JP
Japan
Prior art keywords
cells
express
car
artificial
ligand
Prior art date
Application number
JP2021529003A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513116A (ja
JP7450892B2 (ja
JPWO2020104676A5 (https=
Filing date
Publication date
Priority claimed from EP18208092.9A external-priority patent/EP3656851A1/en
Application filed filed Critical
Publication of JP2022513116A publication Critical patent/JP2022513116A/ja
Publication of JP2022513116A5 publication Critical patent/JP2022513116A5/ja
Publication of JPWO2020104676A5 publication Critical patent/JPWO2020104676A5/ja
Application granted granted Critical
Publication of JP7450892B2 publication Critical patent/JP7450892B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021529003A 2018-11-23 2019-11-22 Ｎｋ細胞のための人工ｈｌａ陽性フィーダー細胞株及びその使用 Active JP7450892B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18208092.9A EP3656851A1 (en) 2018-11-23 2018-11-23 Artificial hla-positive feeder cell lines for nk cells and uses thereof
EP18208092.9 2018-11-23
PCT/EP2019/082283 WO2020104676A1 (en) 2018-11-23 2019-11-22 Artificial hla-positive feeder cell lines for nk cells and uses thereof

Publications (4)

Publication Number Publication Date
JP2022513116A JP2022513116A (ja) 2022-02-07
JP2022513116A5 true JP2022513116A5 (https=) 2022-09-30
JPWO2020104676A5 JPWO2020104676A5 (https=) 2022-09-30
JP7450892B2 JP7450892B2 (ja) 2024-03-18

Family

ID=64664021

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021529003A Active JP7450892B2 (ja) 2018-11-23 2019-11-22 Ｎｋ細胞のための人工ｈｌａ陽性フィーダー細胞株及びその使用

Country Status (5)

Country Link
US (1) US11578307B2 (https=)
EP (2) EP3656851A1 (https=)
JP (1) JP7450892B2 (https=)
CA (1) CA3119403C (https=)
WO (1) WO2020104676A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018060351A1 (en) * 2016-09-29 2018-04-05 Ipsen Biopharm Limited Hybrid neurotoxins
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
KR20220095228A (ko) * 2019-11-06 2022-07-06 베이롤 칼리지 오브 메드신 암의 t 세포 치료를 위한 세포독성 효과기 기억 t 세포를 생산하는 방법
EP4163366A4 (en) * 2020-06-09 2024-08-21 Samsung Life Public Welfare Foundation GENETICALLY MODIFIED CELL LINE FOR ACTIVATION AND AMPLIFICATION OF NK CELLS AND USE THEREOF
CN112048482A (zh) * 2020-09-09 2020-12-08 广东昭泰体内生物医药科技有限公司 一种nk样细胞的培养方法
US12264184B2 (en) * 2021-02-23 2025-04-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. DAP12 constructs and their use to enhance DC vaccines and immunotherapies
US20230149464A1 (en) * 2021-11-18 2023-05-18 Janssen Biotech, Inc. Feeder free cell culture methods for expanding natural killer cell preparations
WO2023096352A1 (ko) * 2021-11-25 2023-06-01 사회복지법인 삼성생명공익재단 Hla-e를 발현하도록 유전적으로 조작된 배양보조세포주, 및 그의 용도
CN117343906A (zh) * 2022-07-04 2024-01-05 上海优卡迪生物医药科技有限公司 表达重组抗原蛋白的饲养细胞及其制备方法和应用
CN115725509B (zh) * 2022-12-09 2025-07-04 上海贝斯昂科生物科技有限公司 一种基因工程细胞的制备及其在nk细胞体外扩增中的应用
KR102669705B1 (ko) * 2023-02-24 2024-06-10 이엔셀 주식회사 제대혈 유래 자연 살해 세포의 확장배양방법
CN116286666B (zh) * 2023-05-15 2023-08-04 成都云测医学生物技术有限公司 滋养层细胞及其制备方法、应用和扩增nk细胞的方法
AU2024351310A1 (en) * 2023-09-25 2026-03-26 Legend Biotech Ireland Limited Modified immune cells and calcineurin inhibitors and uses thereof
GB202317912D0 (en) * 2023-11-23 2024-01-10 Univ College Cardiff Consultants Ltd Viral-based immuno therapeutic
KR20250153112A (ko) * 2024-04-16 2025-10-24 주식회사 유씨아이테라퓨틱스 자연살해세포의 증폭 및 형질 도입 효율 증진용 피더 세포

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4749620A (en) 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
JPH0628570B2 (ja) 1986-02-13 1994-04-20 雪印乳業株式会社 カプセル体の製造方法及び装置
EP0301777A1 (en) 1987-07-28 1989-02-01 Queen's University At Kingston Multiple membrane microencapsulation
US5089272A (en) 1989-03-29 1992-02-18 Snow Brand Milk Products Co., Ltd. Process for producing capsules having a permeability-controllable membrane
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5578442A (en) 1992-03-23 1996-11-26 Vivorx, Inc. Graft copolymers of polycationic species and water-soluble polymers, and use therefor
ATE218893T1 (de) 1993-08-12 2002-06-15 Neurotech Sa Biokompatible immunoisolatorische kapseln, die genetisch veränderte zellen enthalten
WO2012131419A1 (en) * 2011-03-25 2012-10-04 Txcell Method for using regulatory t cells in therapy
WO2012146702A1 (en) * 2011-04-28 2012-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing accessory cells and uses thereof for preparing activated nk cells
EP2893003B1 (en) * 2012-09-04 2021-03-31 Inven2 AS Selective and controlled expansion of educated nk cells
EP3021853A1 (en) * 2013-07-18 2016-05-25 Baylor College Of Medicine Method of enhancing potency of immune cells
EP3223856B1 (en) * 2014-10-27 2025-09-24 University of Central Florida Research Foundation, Inc. Methods and compositions for natural killer cells
GB201616237D0 (en) * 2016-09-23 2016-11-09 Univ Oslo Hf Modulation of function of immune effector cells

Similar Documents

Publication Publication Date Title
JP2022513116A5 (https=)
US20220296690A1 (en) Engineered t cells and uses therefor
JP7781243B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
KR102879284B1 (ko) 항-메소텔린 키메라 항원 수용체(car) 작제물 및 이의 용도
US12304935B2 (en) Immunomodulatory polypeptides and related compositions and methods
CN108884164B (zh) 用于免疫疗法的经修饰细胞
JP2022109953A (ja) 細胞免疫療法のための方法および組成物
US11725053B2 (en) Chimeric antigen receptors comprising a human transferrin epitope sequence
CN109651511B (zh) 一种靶向bcma的嵌合抗原受体及其应用
CN107523545A (zh) 一种高效稳定表达抗体的杀伤性细胞及其用途
CN112955469B (zh) 新型拮抗性抗tnfr2抗体分子
US10023648B2 (en) Anti-TOSO chimeric antigen receptor and its use
JPWO2020104676A5 (https=)
CN113784980A (zh) 人源化抗Claudin18.2嵌合抗原受体及其用途
CN112442126A (zh) 一种抗人cs1抗原的单克隆抗体及其car-t细胞
TWI896517B (zh) 雙專一性抗體及製造與使用其的方法
TW202405177A (zh) 治療自體免疫性疾病之方法及組合物
KR20210115435A (ko) 항-bcma 결합 영역, 이를 포함하는 융합단백질, 및 이를 포함하는 조성물
US20190287013A1 (en) Methods for determining dosing of a therapeutic agent and related treatments
Battin et al. Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents
WO2025148750A1 (zh) 膜表达il-10及其用途
JPWO2022235662A5 (https=)
US20250121007A1 (en) Compositions for the treatment of cancer
CN120529915A (zh) 嵌合抗原受体和抗体-nkg2d配体结构域融合蛋白
HK40041676A (en) Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof